READ THE FULL ETST RESEARCH REPORT
Earth Science Tech, Inc. (OTC: ETST) is a strategic holding company building a vertically integrated healthcare platform across compounding pharmacy, telemedicine, and direct-to-patient fulfillment. Its core subsidiaries include RxCompoundStore.com (a licensed compounding pharmacy operating in 20+ U.S. states), Mister Meds (a Texas-based sterile compounding facility), and Peaks Curative (a telemedicine and compounded medication platform). The company also holds real estate assets under its Avenvi brand and operates a consumer products business. Management’s stated goal is to own as much of the patient journey — from consultation to prescription to delivery — as possible, generating operating leverage across the platform.
Fiscal Year 2026 Results (Year Ended March 31, 2026)
ETST today reported full-year results that underscore the company’s steady financial maturation. Revenue grew 8% to $35.7 million from $33.1 million the prior year. Gross profit rose 5% to $25.5 million, reflecting a 71.4% gross margin. Net income increased 11% to $3.6 million, and total assets grew 27% to $9.0 million. Critically, the company achieved all of this while eliminating all debt — short-term business loans, long-term obligations, and lease liabilities have all been paid off, leaving a clean balance sheet with $7.0 million in stockholders’ equity, up from $3.9 million a year ago. Earnings per share came in at $0.012 per share, up from $0.011 in fiscal 2025. Growth on all meaningful financial measures is a positive sign heading into fiscal 2027.
Progress Over the Last Year
Fiscal 2026 was operationally busy. The company built out Mister Meds’ Texas facility from scratch and launched operations without drawing on debt. It acquired DOConsultation and Villas Health, turned both around, and made them cash flow positive — and their integration strengthened the broader health/wellness segment. The company also rebuilt and relaunched its proprietary telemedicine platform, MyOnlineConsultation (MOC Teledoc), as a prescriber network that was profitable from its first day. Peaks Curative accelerated sharply, surpassing $2 million in revenue in the first week of fiscal Q4 alone. On the real estate side, the first residential unit at Avenvi has been built and is under contract for sale. FINRA also cleared the company’s Form 211 in December, a milestone that had been long in progress. Throughout all of it, ETST repurchased and retired 4.0 million shares during the fiscal year and an additional 3.1 million in just the first quarter of fiscal 2027 — over 7.1 million shares retired in aggregate.
CEO and Chairman Giorgio R. Saumat was direct in his remarks: “In fiscal 2026, we grew revenue, increased earnings, generated positive operating cash flow and strengthened our balance sheet, all while not adding debt to our balance sheet. These results are driven by the work we have done to better integrate the patient experience across our platform, from telemedicine to pharmacy to fulfillment. By owning more of that process, we serve patients effectively while building a stronger and more profitable business.” He added that fiscal 2026 “laid the essential foundation for what management foresees as our next leg of growth,” and pointed to Q1 fiscal 2027 as the period where that trajectory becomes visible in the numbers. He also noted that the company plans to expand the geographic footprint of every subsidiary and will pursue acquisitions and partnerships where they support that goal.
Investment Takeaway
ETST is a debt-free, cash-flow-positive micro-cap executing a coherent vertical integration strategy in a large and growing healthcare market. Revenue, earnings, and assets all grew year-over-year, the balance sheet is materially stronger, and management is actively returning capital through an aggressive share repurchase program. The business is still small, and the OTC listing limits institutional participation, but the operational fundamentals are improving in a consistent and disciplined way. For investors comfortable with the micro-cap risk profile, the combination of profitable growth, zero debt, and demonstrated capital discipline makes ETST a company worth investigating heading into fiscal 2027.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
